title: R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma.
abstract: Stem cell (SC) mobilization is significantly influenced by the mobilization schedule in patients with lymphoma. We evaluated data from 30 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) undergoing SC mobilization. All received R-ESHAP plus a single dose of pegfilgrastim. All patients collected ⩾ 2 × 10(6) CD34+cells/kg, 80% of them at least 5 × 10(6) CD34+cells/kg. Adverse effects of the regimen included myelosuppression and neutropenic fever. Herein, our results suggest that R-ESHAP plus pegfilgrastim is a highly effective mobilization strategy in patients affected by DLBCL associated with a low incidence of adverse events.
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: juanmontorogomez@hotmail.com.
authors.forename: Juan
authors.initials: J
authors.lastname: Montoro
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Giovanna
authors.initials: G
authors.lastname: Andreola
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Angelo
authors.initials: A
authors.lastname: Gardellini
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Babic
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Mara
authors.initials: M
authors.lastname: Negri
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Niccolò
authors.initials: N
authors.lastname: Frungillo
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy.
authors.forename: Daniele
authors.initials: D
authors.lastname: Laszlo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D064592:Autografts; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D011092:Polyethylene Glycols; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D011994:Recombinant Proteins; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D005047:Etoposide; D000069585:Filgrastim; D002945:Cisplatin; D008775:Methylprednisolone
keywords: CD34+ collection; Diffuse large B-cell lymphoma; Pegfilgrastim; R-ESHAP; Stem cell mobilization